Overall verdict
Neutral
5.1/10
1-year performance
-10.40%
Score breakdown
Down 10.4% over 1 year, 66% of the 52-week range.
Strongest: Valuation 8.4/10. Weakest: Profitability 0.0/10.
17 analysts, target +0.0% vs the price.
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.
The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines.
It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Sector
Health Care
Industry
Biotechnology
Primary listing
Asx
Australia
CEO
Gordon Naylor
Founded
1916
Employees
29 000
Revenue / employee
552 628 USD
Next earnings
November 11, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
222.47 AUD
52-week low
90.00 AUD
1-year performance
-10.40%
Declining
Year-to-date performance
3.24%
Declining
Drawdown
-20.46%
Marked drawdown
Position in the 52-week range
66% of range
Range: 190.47 AUD - 324.39 AUD (comparables only)
The price implies growth of 5.91% per year; the company grows at 10.97%.
Gross margin 47.8%, the company loses 15.6% of its revenue, ROIC -8.9%, ROE -14.3%.
Net margin
-15.65%
Negative
Sector -15.24%|S&P 12.97%
Gross margin
47.82%
Low
Return on equity (ROE)
-14.27%
Negative
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
-8.93%
Negative
Free cash flow margin (FCF)
17.59%
High
Margin stability
13.6 pts
Very uneven
Revenue to net income
Growth
2.7/10Revenue up 5.5% over 1 year, 11.0% a year over 5.
Revenue (trailing 12 months)
16.0Md USD
Revenue growth (1y)
5.50%
Moderate
Revenue growth (3y)
18.29%
Solid
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
-2.71%
Revised down
Valuation
8.4/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 29.6x|S&P 23.0x
Forward P/E
20.4x
Fair
EV / EBITDA
13.8x
Cheap
Sector 23.4x|S&P 14.5x
PEG
—
Sector 0.12|S&P 0.86
Fair value (reverse DCF)
257.43 AUD
Deeply undervalued
Market cap
60.5Md USD
Financial strength
6.3/10Cash covers 13.9% of the debt, net debt/EBITDA 1.8x.
Net debt / EBITDA
1.8x
Tight
Gearing (net debt / equity)
57.54%
Solid
Cash
1.5Md USD
Cash / market cap
2.50%
Stretched
Cash / total debt
13.89%
Stretched
Net debt
9.4Md USD
Equity
16.3Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 179.12 AUD
- MM20174.33
- MM50152.76
- MM200142.85
- RSI 1467.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.57%
200-day average slope, 3 months
-9.49%
50-day average slope, 1 month
+18.03%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.23 % per day
Volatility change
-52.05%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 6.07 (10) | 6.23 (17) | 15 766 (17) | 5 090 (17) | 2 823 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 20, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 4 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 7 | CSL | 5.1 | 4.6 | 60.5Md USD | Not meaningful (loss) | -15.6 % | 5.5 % | -8.9 % | 1.8x | 4.7 % | -10.4 % | ||
| 8 | NTRA | 3.8 | 2.3 | 56.3Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 136.1 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
